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the CC BY-NC-ND license (http://creaAbstract Objective: Serum prostate specific antigen (PSA) is commonly used to evaluate
treatment response after definitive radiation therapy (RT). However, PSA levels can tempo-
rarily rise without a clear reason, termed “PSA bounce”, and often engender great anxiety
for both patients and physicians. The present study aimed to determine the prevalence and
factors that predict “PSA bounce” after intensity-modulated radiation therapy (IMRT), and
the relevance to biochemical failure and cancer recurrence in an Asian population.
Methods: We retrospectively reviewed 206 patients who received IMRT for prostate cancer
from 2004 to 2012 in the National Cancer Centre Singapore. These patients were followed
up with regular PSA monitoring. We defined “PSA bounce” as a rise of 0.1 ng/mL, followed
by two consecutive falls. Patients with biochemical failure (PSA nadir þ 2 ng/mL) were further
evaluated for cancer recurrence.
Results: Sixty-one patients (29.6%) experienced “PSA bounce”, at a median time of 16 months
and lasted for 12 months. Age remained the most consistent predictor of the incidence, dura-
tion and extent of “PSA bounce”. Other contributory factors included baseline PSA, Gleason
score and PSA nadir. Hormonal therapy and prostate volume did not affect this phenomenon.
Sixteen patients (7.8%) developed biochemical recurrence, at median time of 32 months, of
which 11 were confirmed to have metastatic disease. The median follow-up time was 71
months.ail.com (Y.G. Tan).
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60 Y.G. Tan et al.Conclusion: A younger age predicts PSA bounce incidence, duration and magnitude. The extent
of bounce appears to be lower in Asian population. The interval to occurrence and extent of
PSA elevation separates PSA bounce from disease recurrence.
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licenses/by-nc-nd/4.0/).Table 1 Patient demographics.
Parameter Value
Age (year), median (range) 68.5 (48.0e85.0)
Risk stratification, n (%) [D’ Amico Classification]
Low 25 (12.1)
Intermediate 69 (33.5)
High 112 (54.4)
Prostate volume (mL), median (range) 31.0 (10.0e97.0)
Adjuvant hormonal therapy, n (%)
Yes 185 (89.8)
No 21 (10.2)1. Introduction
Serum prostate specific antigen (PSA) is a sensitive measure of
treatment outcome for prostate cancer [1]. Although unde-
tectable levels can be expected after a few weeks for pa-
tients undergoing radical prostatectomy, it can take 2e5
years to achieve a nadir PSA level with radiation therapy (RT),
owing to the slower process of tumor-cell killing [2]. More
importantly, it is not uncommon for the PSA levels to rise
temporarily, a phenomenon known as “PSA bounce” [3,4],
first described by Wallner and colleagues in 1997 [5]. While
the exact etiology remains unknown, it is hypothesized to be
the result of prostate cell membrane instability, bacterial and
radiation prostatitis [6]. Although the relevance to biochem-
ical failure remains controversial, these fluctuations can
engender much anxiety amongst the physicians and patients.
The present study is the first to examine PSA bounce
after intensity modulated radiation therapy (IMRT) in an
Asian population. In particular, we reviewed the factors
associated with this phenomenon, in order to stratify the
patient profile that will most likely present with a PSA
bounce. We also looked at the relevance to biochemical
failure and synthesized an approach to help physicians
differentiate between the two entities.
2. Patients and methods
We retrospectively reviewed 206 consecutive patients that
received IMRT for prostate cancer from 2004 to 2012 at the
National Cancer Centre Singapore. Data were obtained from
review of casenotes, cancer registry and electronic records
with IRB approval from the Singhealth Ethics Committee.
None of the patients had nodal or metastatic spread prior to
treatment. A variety of factors were recorded, including the
patients profile, cancer staging and risk group, the
concomitant use of androgen deprivation, the onset,
magnitude and duration of PSA bounce and the time to
biochemical failure. External radiotherapy was delivered via
IMRT, planning for at least 90% of the planning target volume
to receive the prescribed dose (of 70 to 74 Gy).
Given the retrospective nature of this study, follow-ups
were not consistently standardized. However, in our in-
stitution’s follow-up protocol, we recommended quarterly
for the first 2 years post-operatively, semiannually for the
subsequent 3 years and yearly follow-ups onwards. PSA
level and digital rectal examination were done routinely at
follow-ups. We defined PSA bounce as a rise of 0.1 ng/mL,
followed by two consecutive falls. Biochemical failure was
defined according to the Phoenix criteria, a rise of 2 ng/mL
above nadir.Patients with biochemical failure were all further eval-
uated with imaging and bone scan to detect any disease
recurrence.
Statistical analyses were performed using SPSS statistics
version 21.0 (IBM, New York, USA). Uni- and multi-variate
Cox proportional hazard and linear/logistics regression
models were used to stratify and evaluate individual fac-
tor’s contribution. The clinical significance of the results is
taken as p value of <0.05, corresponding to >95% confi-
dence interval.
3. Results
The patient profile and disease characteristics are sum-
marized in Table 1. A total of 206 patients were recruited,
with the median age of 68.5 years old (range: 48.0e85.0
years). Median prostate volume was 31.0 mL (range
10.0e97.0 mL). Transrectal ultrasound biopsy was the most
common method of diagnosis. Risk stratification was based
on the D’Amico classification: 25 patients (12.1%) low risk,
69 (33.5%) intermediate risk, and 112 (54.4%) high risk.
All patients received IMRT ranging from 70 to 74 Gy. One
hundred and eight-five patients (89.8%) received concomi-
tant hormonal therapy. The median time to PSA nadir was 7
months and the median PSA nadir value was 0.03 ng/mL,
partly due to the significant proportion of patients who had
adjuvant hormonal therapy in our study group.
Sixty-one patients (29.6%) experienced the PSA bounce
phenomenon, at a median time of 16 months (range 6e36
months), with a median magnitude of 0.35 ng/mL (range
0.1e4.2 ng/mL) and for a median duration of 12 months
(range 5e38 months) (Table 2). Age was a significant
consistent predictor of PSA bounce. When stratified,
younger patients (aged <65 years) were associated with 3
times higher likelihood to experience bounce (p Z 0.001),
for a longer duration (p Z 0.022) and with greater magni-
tude, although not statistically significant (p Z 0.113).
Table 2 PSA bounce prevalence and statstics.
Parameter Value
PSA bounce, n (%)
Yes 61 (29.6)
No 145 (70.4)
Time to occurrence (month),
median (range)
16 (6e36)
Duration of bounce (month),
median (range)
12 (5e38)
Magnitude of bounce (ng/mL),
median (range)
0.35 (0.1e4.2)
Follow-up time (month),
median (range)
71 (32e116)
Biochemical failure, n (%)
Yes 16 (7.8)
No 190 (92.2)
Disease recurrence, n
Yes 11
No 5
Time to biochemical failure
(month), median (range)
32 (12e59)
Time to disease recurrence
(month), median (range)
36 (16e63)
PSA, prostate specific antigen.
PSA bounce after IMRT 61Other significant factors associated with PSA bounce
included a lower baseline PSA (p Z 0.010), lower Gleason
score (p Z 0.010), low risk prostate cancer (p Z 0.01) and
higher nadir PSA levels post-treatment (p Z 0.020), after
adjusting for confounders on multivariate analysis
(Table 3). On the other hand, hormonal therapy and pre-
treatment prostate volume did not affect the occurrence
of PSA bounce.
The median follow-up time was 71 months (range
32e116 months). Sixteen (7.8%) patients developed
biochemical recurrence, at a median time of 32 months
post-radiation (range 12e59 months), of which 11 (5.3%)
were subsequently confirmed to have clinical disease
recurrence, at a median time of 36 months (range 16e63
months) (Table 2). Of these, nine had systemic metastatic
and two had local recurrences. Four of these 16 patients
had previous PSA bounce. PSA bounce did not seem to
predict a biochemical recurrence or clinical disease
recurrence.Table 3 Factors associated with PSA bounce.
Factor p-Value
Age <65 years 0.001
Duration of bounce 0.022
Magnitude of bounce 0.113
Higher PSA nadir 0.020
Lower PSA at diagnosis 0.010
Lower Gleason score 0.010
Hormonal therapy 0.161
Prostate volume 0.972
PSA, prostate specific antigen.4. Discussion
The PSA bounce phenomenon had been known for some
time [7]. Caloglu and Ciezki [1], in their review article of 11
large case series, detailed that 30%e40% of successfully
treated men would experience a benign PSA bounce,
although the exact range could vary from 15%e84%,
attributed to the several definitions used to describe this
occurrence [8]. The PSA bounces were previously defined as
an increase in 0.1 ng/mL, followed by a subsequent
decrease [6]; an increase of 0.2 ng/mL, followed by a
decline [9,10]; minimal increase of 0.4 ng/mL over a 6-
month period; and a rise of 35% over the previous value
[7]. Similarly, in our study, the PSA bounce was observed in
29.6% of our patients. We adopted a lower threshold of PSA
rise of 0.1 ng/mL, followed by two subsequent falls, as we
believed that any small increment would nonetheless
create much anxiety for our patients. Fig. 1 shows the
extent of PSA bounce in our study.
Our median time to a transient elevation of PSA of 16
months and a median duration lasting 12 months were
consistent with the literature [11,12]. However, the median
magnitude of PSA bounce of 0.35 ng/mL appeared to be much
lower compared to our Western counterparts, which typically
ranged from 0.1 to 1.0 ng/mL [1]. This concurred with the
observation by Satoh et al. [13], in their multi-institutional
pooled analysis of 388 Japanese patients, which they attrib-
uted the lower magnitude to the limited follow-up duration.
Given the long follow-up period in our study, we believe that
there maybe a different mechanism explaining the difference
in PSA bounces between the Asian and Western population,
which required further exploration and studies.
Amongst the various factors (Table 3), age remained the
single most consistent predictor of PSA bounce. Similarly, in
our study, patients aged<65 years old were thrice more likely
to develop a PSA bounce (p Z 0.001). Stock et al. [7] also
reflected 1.5 times more likelihood in the younger patients.
While the exact mechanisms between age and PSA
bounce remained unknown, several hypotheses had been
discussed. Firstly, younger patients would have more
reactive epithelial cells that would affect this phenomenon
[7]. These patients would be more susceptible to post-
radiation prostatitis and cell membrane instability [6].
Similarly, we also identified a higher nadir in patients with
PSA bounce (0.22 vs. 0.08 mL, p Z 0.02) on multivariate
analysis, which may suggest a greater number of post-
treatment epithelial cells corresponding to a greater de-
gree of inflammation, resulting in a PSA elevation, asFigure 1 Extent of PSA bounce. PSA, prostate specific antigen.
Figure 2 Time to PSA bounce and disease recurrence. PSA,
prostate specific antigen.
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prostate volume did not seem to correspond with this
event, we believed that a post-radiation prostate volume
would have given us a better understanding of the rela-
tionship with PSA bounce.
Secondly, younger patients have more androgen pro-
duction, which may stimulate a PSA rise. In the same vein,
we would have expected concomitant hormonal therapy to
influence the bounce phenomenon. Discussion regarding
PSA kinetics in androgen deprivation therapy (ADT) patients
undergoing radiotherapy remained divided [15]. Pickles [16]
commented that the effects of ADT could delay the onset
and lower the magnitude of PSA bounce, but these findings
was not replicated in our study and other large series
[17,18]. Neither was hormonal therapy confounding other
factors in predicting PSA bounce on multivariate analyses.
More importantly, age also influenced the duration and
magnitude of PSA bounce, as previously observed by Critz
et al. [12]. Younger patients not only had a significantly
greater incidence of PSA bounce, but also a longer duration
(14.5 vs. 10.6 months, p Z 0.022) and higher magnitude
(0.66 vs. 0.39 ng/mL) of the phenomenon, although the
latter was not of statistical significance (p Z 0.113).
Cancer grading and staging appeared to influence on the
PSA bounce phenomenon. Patients who experienced the
transient elevation of PSA tended to have a lower Gleason
score (35.5% of patients with Gleason 6e7 compared to 17.9%
of patients with Gleason 8e10, p Z 0.01) and lower initial
PSA levels (16.49 vs. 34.17 ng/mL, p Z 0.01). As such, the
stratified low risk group (D’Amico classification) was most
susceptible to the bounce (pZ 0.01). The higher propensity
for low risk prostate cancer group to develop PSA bounce was
similarly reflected in several larger studies [19,20].
Sixteen patients (7.8%) developed biochemical recur-
rence, defined according to the Phoenix criteria. The
relationship between PSA bounce and biochemical recur-
rence remained undefined. Some studies had suggested a
protective effect of PSA bounce on subsequent biochemical
recurrence [10,11,17] while others [2,6,7,9] did not reveal
any prognostic relevance.
More importantly, the main concern was the likelihood
that the PSA bounce could be an early indicator of disease
recurrence. Under-investigation would risk disease progres-
sion, while over-investigation could engender unnecessary
anxiety and strain healthcare resources. Given the low
recurrence rate in our population, there were limited data to
evaluate the prognostic effect of PSA bounce on disease
recurrence. However, the interval to the onset of PSA rise
remained the single most distinguishing factor that separated
the two entities. In our study, the median time to PSA bounce
was 16 months (range 6e36 months), which was significantly
shorter than the time to disease recurrence of 36 months
(range 16e63 months) (Fig. 2). By the end of 24 months,
86.9% of PSA bounce phenomenon would have occurred. This
observation was reflected in several articles [2,6,10,11],
which re-emphasized the discriminatory intervals to onset of
PSA elevation. Critz et al. [12] commented on a similar
distinction that the median time to cancer recurrence was 30
months compared to PSA bounce of 18 months. However,
there remains a considerable overlap between the two ob-
servations, with three patients developing disease recur-
rence within 2 years of IMRT treatment.Apart from the interval to occurrence, we identified the
magnitude of PSA elevation as another possible discrimi-
natory characteristic. The median PSA rise in the bounce
group was 0.35, compared to 5.3 in those with disease
recurrence. Given the magnitude of PSA bounce is much
lower in an Asian population than the Western counter-
parts, we find greater reason to stick to the Phoenix
criteria, and continue watchful waiting until significant rise
(nadir þ 2 ng/mL) warrants further investigations.
Lastly, we revisited our cancer registry database and
briefly evaluated patients who underwent brachytherapy
(BT) during the time period of this study. All 77 patients,
except one patient, who underwent 125I prostate brachy-
therapy, had low risk prostate cancer, compared to the
12.1% who underwent IMRT in our study. Following BT, there
was a higher proportion of patient (65%) who experienced
PSA bounce, at a shorter median time of 9 months, and
higher median magnitude of 0.50 ng/mL. Pinkawa et al.
[21] also noted similar findings of greater proportion and
higher magnitude of PSA bounce after BT compared to
external beam radiation therapy. He postulated that BT
could have induced a greater local inflammatory response
that explained the differences.
5. Conclusion
To conclude, we believe that PSA bounce remains a sig-
nificant phenomenon in the Asian population, although the
magnitude of bounce appears to be much lower. Age re-
mains the single most consistent predictor of PSA bounce,
its duration and magnitude. Lastly, there remains a clear
distinction between PSA bounce and subsequent biochem-
ical failure or disease recurrence. The interval to occur-
rence and extent of PSA elevation separates these entities.
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